Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

Trial Details

NCT ID
NCT05686798
Phase
PHASE1
Sponsor
Henry Ford Health System
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Subjects with radiologic evidence of intracranial recurrence or progression of a previously diagnosed high-grade astrocytoma.
  • To be eligible for this trial, the subjects must have:
  • Histologically documented glioblastomas or anaplastic astrocytoma prior to the debulking surgery that is suspicious to have progressed on imaging. …
  • Patients must be ≥ 18 years of age, able to provide informed consent and express a willingness to meet all the expected requirements of the protoco…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →